The use of bone-modifying agents in multiple myeloma
Munawwar Hussain1, Fatima Khan2, Samer Al Hadidi1
1Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Blood Reviews
|September 1, 2022
Summary
Bone-modifying agents like bisphosphonates help manage multiple myeloma bone disease by reducing pain and fracture risk. However, their impact on overall survival remains uncertain.
Area of Science:
- Hematology
- Oncology
- Bone Biology
Background:
- Multiple myeloma involves abnormal plasma cell proliferation in bone marrow.
- This leads to myeloma bone disease, characterized by pain and skeletal events.
- Current treatments like bisphosphonates and denosumab manage symptoms but don't repair bone.
Purpose of the Study:
- To review bone-modifying agents for myeloma bone disease.
- To discuss their mechanisms, initiation, duration, and survival benefits.
Main Methods:
- Literature review of bone-modifying agents.
- Analysis of treatment protocols and survival data.
Main Results:
- Bone-modifying agents decrease bone pain and fracture risk.
- These agents do not stimulate new bone formation or repair existing damage.
- The effect of these agents on overall survival is not yet established.
Conclusions:
- Bone-modifying agents are crucial for managing myeloma bone disease symptoms.
- Further research is needed to determine if these agents improve overall survival in multiple myeloma patients.
Related Concept Videos
01:40Bone Remodeling
38.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.5K
01:29Bone Disorders
3.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.8K
01:31Osteoclasts in Bone Remodeling
3.1K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.1K
01:22Bone Marrow Sampling and Transplants
482
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
482